Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Atmar

Showing results (211-220 of 237) with videos related to

Pageof 24
Sort By:
Scientific Reports|July 2, 2025
Complete genomic characterization of global pathogens respiratory syntical virus and human norovirus using probe based capture enrichmentSravya V Bhamidipati, Anil Surathu, Hsu Chao, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Complete Genomic Characterization of Global Pathogens, Respiratory Syncytial Virus (RSV), and Human Norovirus (HuNoV) Using Probe-based Capture EnrichmentSravya V Bhamidipati, Anil Surathu, Hsu Chao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US AdultsChristina A Rostad, Robert L Atmar, Emmanuel B Walter, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science Translational Medicine|February 25, 2026
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boostNoemia S Lima, Lauren McCormick, Samuel Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron NeutralizationNicole A Doria-Rose, Xiaoying Shen, Stephen D Schmidt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2023
Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the GambiaLauren M Schwartz, Jennifer Oshinsky, Mardi Reymann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|April 29, 2025
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 VaccineRobert L Atmar, Kirsten E Lyke, Christine M Posavad, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Pageof 24

Showing results (211-220 of 237) with videos related to

Sort By:
Pageof 24
Scientific Reports|July 2, 2025
Complete genomic characterization of global pathogens respiratory syntical virus and human norovirus using probe based capture enrichmentSravya V Bhamidipati, Anil Surathu, Hsu Chao, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Complete Genomic Characterization of Global Pathogens, Respiratory Syncytial Virus (RSV), and Human Norovirus (HuNoV) Using Probe-based Capture EnrichmentSravya V Bhamidipati, Anil Surathu, Hsu Chao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US AdultsChristina A Rostad, Robert L Atmar, Emmanuel B Walter, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science Translational Medicine|February 25, 2026
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boostNoemia S Lima, Lauren McCormick, Samuel Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron NeutralizationNicole A Doria-Rose, Xiaoying Shen, Stephen D Schmidt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2023
Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the GambiaLauren M Schwartz, Jennifer Oshinsky, Mardi Reymann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|April 29, 2025
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 VaccineRobert L Atmar, Kirsten E Lyke, Christine M Posavad, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Pageof 24